Ua ʻike pinepine nā ʻāina waiwai i ka pono e hōʻoia i ke komo ʻana i nā lāʻau āpau COVID-19 a puni ka honua.
Eia nō naʻe, nā pilikia o ka mālama ʻana i ka lāʻau lapaʻau a me nā koho kūʻai nui a nā ʻāina waiwai a me nā ʻāina loaʻa haʻahaʻa.
ʻO Google ia - ʻAʻohe mea palekana a palekana nā kānaka āpau.

Kuhi ʻia kahi noi no India a me ʻApelika Hema e ʻae ʻia nā palapala kūʻē e kūʻē iā COVID-19 i ka manawa o ka hālāwai WTO, ʻoiai ke kākoʻo nui o nā hui lālā o ka hui. Ua kāpae ʻia kēia noi i nā kuleana ʻona ʻona ʻē aʻe pū kekahi, akā ʻo ka wahi nui o ka paio ma waena o nā ʻāina waiwai a me nā ʻilihuna ka kaua lāʻau lapaʻau.

Ma waena o Nowemapa a me Malaki, ua ʻike pinepine nā ʻāina waiwai (G20 ma Abu Dhabi a me G7 ma Geneva) ka pono e hōʻoia i ke komo ʻana i lāʻau āpau no nā mea āpau. Kaulana loa (aneane 84 miliona mau hopena i ka huli ʻana ma Google) ʻo ia ka ʻōlelo: "ʻAʻohe mea palekana a hiki i ka palekana o nā mea āpau." Eia nō naʻe, ke kūpaʻa o ka pākēneka o nā lāʻau lapaʻau i hana ʻia ma nā ʻāina he 10 mua (75.5% o ka huina o nā lāʻau āpau, a piʻi aʻe i 83.3% inā manaʻo kekahi i ka 15 mua) e hāpai i nā kānalua e pili ana i ka hopena o nā hana paʻa. ua hōʻoia e ka hoʻopaʻapaʻa WTO.

I kēia hoʻopaʻapaʻa, ua hoʻokūpaʻa nā ʻāina waiwai iā lākou iho ma hope o nā paio 2: hoʻokahi maʻamau - noiʻi a me nā hana hou e hōʻoia i ka hōʻoia a me ka pale ʻana i nā kuleana waiwai ʻona, a me nā kikoʻī ʻē aʻe - ʻaʻole hiki ke kau ʻia ka hopena no ka hoʻonui ʻana i ka lako o ka lāʻau lapaʻau.

Hilahila hilahila ʻole kēia hoʻopaʻapaʻa hope loa i ka mālama ʻana i ka lāʻau lapaʻau a me nā koho kūʻai nunui a nā ʻāina waiwai. Ua ʻōlelo pinepine ʻia ua hana ʻo Kanada i nā hoʻohiki e ʻae ai i ka wīlika ma kahi o 5 mau manawa o kona heluna kanaka. Akā ʻaʻole kū hoʻokahi kēia hihia. ʻO kahi laʻana, ʻo Italia, nona ka heluna kanaka ma kahi o 60 miliona, ua kau inoa i nā ʻaelike e loaʻa i ka hopena o 2022, 40 miliona AstraZeneca mahele, 65.8 Pfizer, 26.6 Johnson a me Johnson, 40.4 Sanofi, 29.9 Curevac, a me 39.8 Moderna. ʻO ke kumukūʻai i manaʻo ʻia, e like me kā Ms. De Bleeker i loko o kahi paʻi paʻi ʻole o ka papa inoa o nā kumukūʻai, 3 mau mahina i hala aku nei, he 2.5 biliona kālā ia, akā mai ia manawa ua hoʻonui ʻia kekahi mau kumukūʻai.

ʻO kēia kumukūʻai he 1% o ke kālā hoʻihoʻi i hāʻawi ʻia iā ʻItalia e ka European Union a e hōʻike ana e pili ana i ka 10% o ka nui GNP o nā ʻāina Sub-Saharan. ʻO kahi leka Associated Press o hoʻokahi mahina i hala aku nei e hōʻike ana i nā kumukūʻai ʻokoʻa i uku ʻia e nā ʻāina ʻokoʻa e pili ana i nā kumukūʻai hana kūloko a me ka nui o ke kauoha a ʻo ka ʻōlelo i hoʻolaha pinepine ʻia e uku paha nā ʻāina ʻilihune i ka manaʻo nui. (Maria Cheng lāua ʻo Lori Hinnant, Malaki 1)

ʻO kekahi paio e hiki i nā ʻāina waiwai wale nō ke hana i nā lāʻau lapaʻau.

He wahaheʻe maoli kēia.

He aha e lawe ʻia mai kēia ʻatikala:

An Associated Press note of one month ago underscored that the different prices paid by different countries depend on local production costs and size of the order and that the often announced statement that poor countries might pay less may have been wishful thinking.
Between November and March, rich countries have repeatedly recognized (G20 in Abu Dhabi and G7 in Geneva) the need to guarantee access to vaccines for all.
This cost is 1% of the recovery fund granted to Italy by the European Union and would represent about the 10% of Sub-Saharan countries' total GNP.